4月18日，据CDE官网消息，普方生物制药（苏州）有限公司联合申请药品“注射用GEN1184”，获得临床试验默示许可，受理号CXSB2500023。
公示信息显示，药品“注射用GEN1184”适应症：用于局部晚期和/或转移性实体瘤患者 。
普方生物制药（苏州）有限公司，成立于2019年，位于苏州市，是一家以从事研究和试验发展为主的企业。企业注册资本30000万人民币，实缴资本7110.68万人民币。
通过天眼查大数据分析，普方生物制药（苏州）有限公司参与招投标项目6次，知识产权方面有商标信息3条，专利信息2条，此外企业还拥有行政许可11个。
主要股东信息显示，普方生物制药（苏州）有限公司由ProfoundBio Limited持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.